RhumbLine Advisers
OBIO icon

RhumbLine Advisers’s Orchestra BioMed OBIO Stock Holding History

RhumbLine Advisers’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-31,657
Closed -$135K – 4224
2025
Q1 		$135K Buy
31,657
+914
+3% +$4.54K ﹤0.01% 3285
2024
Q4 		$123K Buy
30,743
+1,196
+4% +$6.42K ﹤0.01% 3415
2024
Q3 		$152K Buy
29,547
+3,108
+12% +$20.3K ﹤0.01% 3362
2024
Q2 		$215K Buy
26,439
+17,405
+193% +$101K ﹤0.01% 3191
2024
Q1 		$47.6K Buy
9,034
+606
+7% +$4.11K ﹤0.01% 3635
2023
Q4 		$76.9K Buy
8,428
+874
+12% +$5.97K ﹤0.01% 3526
2023
Q3 		$65.9K Buy
7,554
+4,379
+138% +$29.4K ﹤0.01% 3585
2023
Q2 		$22.2K Buy
+3,175
New +$48.2K ﹤0.01% 3797

Other funds holding OBIO

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RhumbLine Advisers's OBIO Position: Q2 2025 in Review

RhumbLine Advisers sold out of Orchestra BioMed (OBIO) in Q2 2025, closing a stake of 31,657 shares — an estimated $135K sold.

RhumbLine Advisers first reported a position in OBIO in Q2 2023 and held it in 8 quarters. The position peaked at $215K in Q2 2024. 59 funds tracked by Wall St. Rank hold OBIO as of Q2 2025.

  • RhumbLine Advisers reported no remaining Orchestra BioMed position as of Q2 2025 after selling out during the quarter.
  • RhumbLine Advisers sold 31,657 Orchestra BioMed shares in Q2 2025, an estimated $135K.
  • RhumbLine Advisers first reported a position in Orchestra BioMed in Q2 2023 and held it in 8 quarters.
  • RhumbLine Advisers's Orchestra BioMed position peaked at $215K in Q2 2024.
  • 59 funds tracked by Wall St. Rank held Orchestra BioMed as of Q2 2025.

Based on RhumbLine Advisers's 13F filing for Q2 2025, filed 12 Aug 2025.